SARS⁃CoV⁃2非结构蛋白16研究进展  

Research progress in NSP16 of SARS⁃CoV⁃2

作　　者：赵文宇 葛常辉 吴永革 ZHAO Wenyu;GE Changhui;WU Yongge(National Engineering Laboratory for AIDS Vaccine,School of Life Sciences,Jilin University,Changchun 130012,China;Beijing Key Laboratory for Radiobiology,Institute of Radiation Medicine,Academy of Military Medical Sciences,Academy of Military Sciences,Beijing 100850,China)

机构地区：[1]吉林大学生命科学学院,艾滋病疫苗国家工程实验室,长春130012 [2]军事科学院军事医学研究院辐射医学研究所,放射生物学北京市重点实验室,北京100850

出　　处：《军事医学》2023年第11期872-875,878,共5页Military Medical Sciences

摘　　要：在新型冠状病毒(SARS⁃CoV⁃2)感染过程中,病毒编码的非结构蛋白(NSP)在宿主细胞内先于病毒RNA产生,首先形成复制⁃转录复合体,SARS⁃CoV⁃2基因组依赖复制⁃转录复合体得以在宿主细胞内完成正常复制。该文对在SARS⁃CoV⁃2感染早期出现并参与病毒RNA合成的非结构蛋白16(NSP16)的结构和生物学功能及其药物研究进展进行综述,为SARS⁃CoV⁃2引发疾病的预防和治疗提供新思路。Non⁃structural protein(NSP)appears in host cells earlier than viral RNA during SARS⁃CoV⁃2 infections.NSP forms replication and transcription complexes before SARS⁃CoV⁃2 finishes normal viral replication in host cells based on these complexes.This article reviews the structure,biological function and advances in drug research of NSP16,which appears in the early stage of SARS⁃CoV⁃2 infection and play a significant role in viral RNA formation.This article is expected to provide new ideas for prevention and treatment of diseases caused by SARS⁃CoV⁃2.

关 键 词：新型冠状病毒 病毒复制 非结构蛋白 非结构蛋白16 

分 类 号：R373.19[医药卫生—病原生物学]